Do analysts rate VECT or ACOG?

Alpha Cognition has a consensus price target of $14.67, indicating a potential upside of 122.90%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, VECT or ACOG?

VectivBio has higher earnings, but lower revenue than Alpha Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VectivBio N/A N/A N/A N/A N/A Alpha Cognition $10.22M 14.02 -$20.67M -$1.35 N/A

Does the media refer more to ACOG or PRME?

In the previous week, Prime Medicine had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.59 beat Prime Medicine's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACOG or TECX?

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 1.59 beat Tectonic Therapeutic's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACOG or AQST?

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Alpha Cognition. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.59 beat Aquestive Therapeutics' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alpha Cognition (ACOG) Competitors

$6.58 +0.01 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$6.62 +0.04 (+0.53%)

As of 04:10 PM Eastern

Compare

ACOG vs. VECT, PRME, TECX, DNA, and AQST

Should you buy Alpha Cognition stock or one of its competitors? MarketBeat compares Alpha Cognition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Cognition include VectivBio (VECT), Prime Medicine (PRME), Tectonic Therapeutic (TECX), Ginkgo Bioworks (DNA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Cognition compare to VectivBio?

VectivBio (NASDAQ:VECT) and Alpha Cognition (NASDAQ:ACOG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

In the previous week, Alpha Cognition had 1 more articles in the media than VectivBio. MarketBeat recorded 1 mentions for Alpha Cognition and 0 mentions for VectivBio. Alpha Cognition's average media sentiment score of 1.59 beat VectivBio's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
VectivBio	Neutral
Alpha Cognition	Very Positive

VectivBio has higher earnings, but lower revenue than Alpha Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	N/A	N/A	N/A	N/A	N/A
Alpha Cognition	$10.22M	14.02	-$20.67M	-$1.35	N/A

VectivBio has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. VectivBio's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Alpha Cognition	-232.23%	-58.35%	-45.99%

Alpha Cognition has a consensus price target of $14.67, indicating a potential upside of 122.90%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Alpha Cognition beats VectivBio on 6 of the 9 factors compared between the two stocks.

How does Alpha Cognition compare to Prime Medicine?

Alpha Cognition (NASDAQ:ACOG) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Prime Medicine had 1 more articles in the media than Alpha Cognition. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.59 beat Prime Medicine's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition presently has a consensus price target of $14.67, suggesting a potential upside of 122.90%. Prime Medicine has a consensus price target of $7.38, suggesting a potential upside of 136.38%. Given Prime Medicine's higher possible upside, analysts plainly believe Prime Medicine is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Alpha Cognition has a net margin of -232.23% compared to Prime Medicine's net margin of -4,917.55%. Alpha Cognition's return on equity of -58.35% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

70.4% of Prime Medicine shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alpha Cognition has higher revenue and earnings than Prime Medicine. Alpha Cognition is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	14.02	-$20.67M	-$1.35	N/A
Prime Medicine	$4.63M	121.71	-$201.14M	-$1.23	N/A

Alpha Cognition has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Summary

Prime Medicine beats Alpha Cognition on 9 of the 17 factors compared between the two stocks.

How does Alpha Cognition compare to Tectonic Therapeutic?

Alpha Cognition (NASDAQ:ACOG) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Alpha Cognition and Alpha Cognition both had 1 articles in the media. Alpha Cognition's average media sentiment score of 1.59 beat Tectonic Therapeutic's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tectonic Therapeutic has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Tectonic Therapeutic's return on equity of -32.33% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Alpha Cognition has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, suggesting that its share price is 219% more volatile than the broader market.

Alpha Cognition has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	14.02	-$20.67M	-$1.35	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Alpha Cognition currently has a consensus price target of $14.67, suggesting a potential upside of 122.90%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 158.46%. Given Tectonic Therapeutic's higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Tectonic Therapeutic beats Alpha Cognition on 9 of the 14 factors compared between the two stocks.

How does Alpha Cognition compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Alpha Cognition has lower revenue, but higher earnings than Ginkgo Bioworks. Alpha Cognition is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.72	-$312.76M	-$5.36	N/A
Alpha Cognition	$10.22M	14.02	-$20.67M	-$1.35	N/A

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential downside of 12.40%. Alpha Cognition has a consensus price target of $14.67, suggesting a potential upside of 122.90%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Alpha Cognition had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 1 mentions for Alpha Cognition and 0 mentions for Ginkgo Bioworks. Alpha Cognition's average media sentiment score of 1.59 beat Ginkgo Bioworks' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Alpha Cognition	Very Positive

Ginkgo Bioworks has a net margin of -215.41% compared to Alpha Cognition's net margin of -232.23%. Ginkgo Bioworks' return on equity of -56.08% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Alpha Cognition	-232.23%	-58.35%	-45.99%

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Summary

Alpha Cognition beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Aquestive Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Alpha Cognition. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 1.59 beat Aquestive Therapeutics' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Aquestive Therapeutics has a net margin of -137.08% compared to Alpha Cognition's net margin of -232.23%. Aquestive Therapeutics' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Alpha Cognition has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	14.02	-$20.67M	-$1.35	N/A
Aquestive Therapeutics	$44.54M	14.07	-$83.78M	-$0.61	N/A

Alpha Cognition presently has a consensus price target of $14.67, indicating a potential upside of 122.90%. Aquestive Therapeutics has a consensus price target of $8.50, indicating a potential upside of 70.17%. Given Alpha Cognition's higher probable upside, equities analysts clearly believe Alpha Cognition is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Aquestive Therapeutics beats Alpha Cognition on 9 of the 16 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACOG vs. The Competition

Export

Metric	Alpha Cognition	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$143.16M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.87	20.50	25.39	23.96
Price / Sales	14.02	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.28	8.26	10.76	6.41
Net Income	-$20.67M	$23.91M	$3.56B	$337.14M
7 Day Performance	-1.50%	3.05%	1.37%	-0.48%
1 Month Performance	12.48%	2.40%	0.81%	0.49%
1 Year Performance	-25.98%	56.35%	30.53%	28.16%

Alpha Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACOG Alpha Cognition	4.2689 of 5 stars	$6.58 +0.2%	$14.67 +122.9%	-27.0%	$143.16M	$10.22M	N/A	N/A	News Coverage Positive News
VECT VectivBio	N/A	$16.85 flat	N/A	N/A	$573.24M	$27.34M	N/A	30	High Trading Volume
PRME Prime Medicine	1.627 of 5 stars	$3.15 +9.6%	$7.65 +143.2%	N/A	$568.05M	$4.63M	N/A	N/A	Analyst Forecast
TECX Tectonic Therapeutic	2.4506 of 5 stars	$29.67 -1.1%	$79.40 +167.6%	+63.1%	$559.87M	N/A	N/A	120
DNA Ginkgo Bioworks	0.1601 of 5 stars	$8.52 +3.8%	$8.50 -0.2%	+3.9%	$556.53M	$170.15M	N/A	640	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACOG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Cognition (ACOG) Competitors

ACOG vs. VECT, PRME, TECX, DNA, and AQST

How does Alpha Cognition compare to VectivBio?

Summary

How does Alpha Cognition compare to Prime Medicine?

Summary

How does Alpha Cognition compare to Tectonic Therapeutic?

Summary

How does Alpha Cognition compare to Ginkgo Bioworks?

Summary

How does Alpha Cognition compare to Aquestive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Cognition (ACOG) Competitors

ACOG vs. VECT, PRME, TECX, DNA, and AQST

How does Alpha Cognition compare to VectivBio?

Does the media favor VECT or ACOG?

Which has preferable valuation & earnings, VECT or ACOG?

Is VECT or ACOG more profitable?

Do analysts rate VECT or ACOG?

Summary

How does Alpha Cognition compare to Prime Medicine?

Does the media refer more to ACOG or PRME?

Do analysts prefer ACOG or PRME?

Is ACOG or PRME more profitable?

Do insiders and institutionals hold more shares of ACOG or PRME?

Which has higher earnings & valuation, ACOG or PRME?

Which has more risk & volatility, ACOG or PRME?

Summary

How does Alpha Cognition compare to Tectonic Therapeutic?

Does the media favor ACOG or TECX?

Do insiders & institutionals have more ownership in ACOG or TECX?

Is ACOG or TECX more profitable?

Which has more risk & volatility, ACOG or TECX?

Which has better valuation and earnings, ACOG or TECX?

Do analysts recommend ACOG or TECX?

Summary

How does Alpha Cognition compare to Ginkgo Bioworks?

Which has stronger earnings & valuation, DNA or ACOG?

Do analysts recommend DNA or ACOG?

Does the media refer more to DNA or ACOG?

Is DNA or ACOG more profitable?

Do institutionals and insiders hold more shares of DNA or ACOG?

Which has more volatility & risk, DNA or ACOG?

Summary

How does Alpha Cognition compare to Aquestive Therapeutics?

Do insiders & institutionals believe in ACOG or AQST?

Does the media prefer ACOG or AQST?

Which has more volatility and risk, ACOG or AQST?

Is ACOG or AQST more profitable?

Which has better earnings & valuation, ACOG or AQST?

Do analysts recommend ACOG or AQST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools